STOCK TITAN

MIRA Pharmaceuticals shareholders reelect board

MIRA Pharmaceuticals’ 2026 annual meeting achieved a 63.06% quorum, electing all director nominees and ratifying Salberg & Company, P.A. as auditor.

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

MIRA Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on September 11, 2026, with 26,499,076 common shares present in person or by proxy out of 42,022,087 outstanding, representing a 63.06% quorum. Stockholders elected all five nominated directors to serve until the next annual meeting and until their successors are elected and qualified. Stockholders also approved the ratification of Salberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026, and approved a proposal allowing adjournment of the meeting, if necessary, to solicit additional proxies for the director and auditor proposals.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Shares outstanding as of record date 42,022,087 shares Common stock outstanding as of July 21, 2026, the record date
Shares present or represented 26,499,076 shares Shares present or represented by proxy at the 2026 Annual Meeting
Quorum percentage 63.06% Portion of outstanding shares represented at the 2026 Annual Meeting
Votes for CEO Erez Aminov as director 20,559,502 votes Votes for election of director Erez Aminov; 226,540 votes withheld and 5,713,034 broker non-votes
Votes for auditor ratification 25,950,852 votes Votes for ratifying Salberg & Company, P.A. as independent registered public accounting firm
Votes against auditor ratification 158,064 votes Votes against ratifying Salberg & Company, P.A.
Votes for adjournment proposal 24,897,741 votes Votes for the proposal to approve adjournment of the Annual Meeting, if necessary
Votes against adjournment proposal 1,205,307 votes Votes against the adjournment proposal
Record Date financial
"The record date for stockholders entitled to notice of the Annual Meeting was July 21, 2026"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
quorum financial
"26,499,076 shares of Common Stock were present or represented by proxy, constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"Votes For | | Votes Withheld | | Broker Non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
adjournment of the Annual Meeting financial
"approved a proposal to approve an adjournment of the Annual Meeting, if necessary"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What matters did MIRA (MIRA) stockholders vote on at the 2026 Annual Meeting?

Stockholders voted on three proposals: election of five directors, ratification of Salberg & Company, P.A. as independent registered public accounting firm for 2026, and approval of a proposal to adjourn the meeting, if necessary, to solicit additional proxies for the first two proposals.

What was the shareholder turnout for MIRA (MIRA)’s 2026 Annual Meeting?

As of the record date, MIRA had 42,022,087 common shares outstanding. At the 2026 Annual Meeting, 26,499,076 shares were present or represented by proxy, representing approximately 63.06% of the outstanding shares entitled to vote.

Were all director nominees elected at MIRA (MIRA)’s 2026 Annual Meeting?

Yes. All five nominees—Erez Aminov, Matthew Whalen, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson—were elected as directors to serve until the next annual meeting and until their successors are duly elected and qualified.

Which audit firm did MIRA (MIRA) stockholders ratify for fiscal year 2026?

Stockholders approved the ratification of Salberg & Company, P.A. as MIRA Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with 25,950,852 votes for, 158,064 votes against, and 390,160 abstentions.

Did MIRA (MIRA) stockholders approve the adjournment proposal at the 2026 Annual Meeting?

Yes. Stockholders approved a proposal to allow adjournment of the Annual Meeting, if necessary, to solicit additional proxies for the director and auditor items, with 24,897,741 votes for, 1,205,307 votes against, and 396,028 abstentions.

How many votes did MIRA (MIRA) CEO Erez Aminov receive for director election?

For the election of director Erez Aminov, stockholders cast 20,559,502 votes for and 226,540 votes withheld, with 5,713,034 broker non-votes recorded on this proposal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001904286 0001904286 2026-09-11 2026-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report: September 11, 2026

 

 

MIRA PHARMACEUTICALS, INC.

 

(Exact Name of Registrant as Specified in its Charter)

 

Florida   001-41765   85-3354547
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida 33131

(Address of Principal Executive Offices)

 

(786) 432-9792

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.07. Submission of a Matter to a Vote of Security Holders.

 

On September 11, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of the Annual Meeting was July 21, 2026 (the “Record Date”). As of the Record Date, there were 42,022,087 shares of common stock, par value $0.0001 per share (“Common Stock”) of the Company outstanding. Each share of Common Stock represents one vote that could be voted on each matter that came before the Annual Meeting.

 

At the Annual Meeting, 26,499,076 shares of Common Stock were present or represented by proxy, constituting a quorum for the Annual Meeting. The 26,499,076 votes represented equaled approximately 63.06% of the outstanding shares entitled to vote.

 

At the Annual Meeting, three proposals were submitted to the Company’s stockholders. The proposals are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on July 28, 2026. Each proposal was approved by the Company’s stockholders.

 

The final voting results were as follows:

 

Proposal 1

 

The Company’s stockholders elected Erez Aminov, Matthew Whalen, Matthew Del Giudice, M.D., Denil Nanji Shekhat M.D., and Edward MacPherson, as directors of the Company to serve until the next Annual Meeting of Stockholders, or until their respective successors have been duly elected and qualified, based upon the voting results set forth below.

 

Nominee  Votes For  Votes Withheld  Broker Non-votes
Erez Aminov  20,559,502  226,540  5,713,034
Matthew Pratt Whalen  20,560,180  225,862  5,713,034
Matthew Del Giudice, M.D.  20,558,412  227,630  5,713,034
Denil Nanji Shekhat, M.D.  20,138,206  647,83  5,713,034
Edward MacPherson  20,435,527  350,515  5,713,034

 

Proposal 2

 

The Company’s stockholders approved the ratification of the appointment of Salberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, based upon the voting results set forth below.

 

Votes For   Votes Against   Votes Abstained   Broker Non-votes
25,950,852   158,064   390,160   -

 

 

Proposal 3

 

The Company’s stockholders approved a proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1 and 2.

 

Votes For   Votes Against   Votes Abstained   Broker Non-votes
24,897,741   1,205,307   396,028   -

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
     
Dated: September 16, 2026 By: /s/ Erez Aminov
  Name: Erez Aminov
  Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading